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. However, in contrast to other subsequently published guidelines [2] [3] [4] [5] [6] [7] [8] [9] [10] , these recommendations are considered by some to be overly conservative and restrictive with respect to patient selection, repeat cholesterol measurements and escalation of lipid-lowering therapy, as well as to possibly encourage a nihilistic approach, particularly in patients who require dialysis 11, 12 .
To some extent these issues are related to the historical unavailability of low-cost, efficacious and welltolerated non-statin-based lipid-lowering therapies. However, developments in the understanding of lipid metabolism, increasing evidence supporting the use of novel lipid-lowering therapies, emerging clinical data and the publication of guidelines from learned societies mean that nephrologists and other health professionals may now have to reconsider their attitude towards the use of such therapies in patients with CKD and ESRD.
Here we review the epidemiology, pathogenesis and treatment of dyslipidaemia in patients with CKD or ESRD and in kidney transplant recipients. We discuss the mechanisms of action of novel lipid-lowering agents, evaluate the emerging evidence that supports the use of these therapies and discuss the potential health economic implications of their adoption in clinical practice. Finally, we reappraise the 2013 KDIGO Clinical Practice Guideline for Lipid Management in CKD 1 in the context of the currently available data and more recent lipid management guidelines from other societies.
Renal function and cardiovascular risk A graded inverse relationship exists between estimated glomerular filtration rate (eGFR) and cardiovascular disease, which is independent of age, sex and other conventional cardiovascular risk factors 13, 14 . This relationship is present even in the setting of minor renal impairment, with most studies showing an increased risk of cardiovascular disease at an eGFR <60 ml/min/1.73 m 2 and some studies showing an increased number of cardiovascular events even at higher levels of eGFR [13] [14] [15] . Moreover, patients with ESRD who require dialysis have an extremely high risk of cardiovascular events 16 . 13 , Gerard London 14 , Alberto Ortiz 15 and Carmine Zoccali 8 Abstract | An increased risk of cardiovascular disease, independent of conventional risk factors, is present even at minor levels of renal impairment and is highest in patients with end-stage renal disease (ESRD) requiring dialysis. Renal dysfunction changes the level, composition and quality of blood lipids in favour of a more atherogenic profile. Patients with advanced chronic kidney disease (CKD) or ESRD have a characteristic lipid pattern of hypertriglyceridaemia and low HDL cholesterol levels but normal LDL cholesterol levels. In the general population, a clear relationship exists between LDL cholesterol and major atherosclerotic events. However, in patients with ESRD, LDL cholesterol shows a negative association with these outcomes at below average LDL cholesterol levels and a flat or weakly positive association with mortality at higher LDL cholesterol levels. Overall, the available data suggest that lowering of LDL cholesterol is beneficial for prevention of major atherosclerotic events in patients with CKD and in kidney transplant recipients but is not beneficial in patients requiring dialysis. The 2013 Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for Lipid Management in CKD provides simple recommendations for the management of dyslipidaemia in patients with CKD and ESRD. However, emerging data and novel lipid-lowering therapies warrant some reappraisal of these recommendations.
*e-mail: charles.ferro@ uhb.nhs.uk standardized cardiovascular and non-cardiovascular mortality are 8.1-fold and 8.8-fold higher, respectively, in patients on dialysis than in the general population 17 . The mortality of patients with ESRD is twice as high as that of patients with congestive heart failure and four times that of patients with diabetes mellitus in the absence of CKD 16 . In all relevant studies of patients with early CKD or ESRD published to date, cardiovascular disease is the predominant cause of this increased mortality, accounting for over 50% of all deaths 13, 14, 16, 18 . Kidney transplantation is the treatment of choice for patients with ESRD and is associated with healthcare cost savings, improved quality of life and improved survival [19] [20] [21] [22] . Candidates for kidney transplantation undergo rigorous cardiovascular investigations 23 . However, cardio vascular mortality still accounts for approximately 50% of all deaths in kidney transplant recipients 24 .
Dyslipidaemia in kidney disease
Patients with kidney disease are a very heterogeneous population with a wide range of aetiologies of renal damage, levels of renal function and proteinuria, comorbidities (especially concurrent diabetes), renal replacement modalities and treatments, all of which can affect the levels and properties of circulating lipids 25, 26 . In general, renal dysfunction changes the level, composition and quality of these lipids in favour of a more atherogenic profile [27] [28] [29] [30] . The characteristic lipid pattern in patients with CKD stage 3 or higher consists of hypertriglyceridaemia, low levels of HDL cholesterol and variable levels of LDL cholesterol and total cholesterol 27, 28, [31] [32] [33] [34] .
Lipid metabolism
Lipid metabolism is complex and involves multiple organs, cells and tissues, including the liver, intestine, plasma, macrophages and vascular endothelium, all of which can be affected by impaired kidney function 28, 35 ( Fig. 1) . As fats are hydrophobic and generally insoluble in plasma 35 they are encased by surface apolipoproteins and phospholipids, creating water-soluble lipoprotein particles. Hundreds of apolipoproteins exist [35] [36] [37] ; these also act as cofactors and ligands for lipid-processing enzymes.
Dyslipidaemia in patients with CKD occurs as a result of altered metabolism of postprandial lipoproteins and other triglyceride-rich lipoproteins (such as very low density lipoprotein (VLDL), intermediate density lipoprotein (IDL) and LDL), changes in reverse cholesterol transport and lipoprotein structure, post-translational modification of lipoproteins and increased levels of lipoprotein(a) (Lp(a)).
Lipoprotein structure LDL cholesterol has been a major focus of cardiovascular risk reduction in patients with CKD 25, 27, 28, 31, 33, [38] [39] [40] [41] . However, the levels of LDL cholesterol and total cholesterol are often within normal limits in these patie nts 27, 28, 33, 34, [41] [42] [43] [44] . Alterations in lipoprotein structure, for example an increased predominance of atherogenic small dense LDL particles, might be more important than quantitative changes in cholesterol levels in patients with CKD 27, 28, [41] [42] [43] [44] . The increased pro-atherogenic potential of small dense LDL particles has been linked to their increased capacity to infiltrate the arterial intima and their increased susceptibility to oxidative modification compared with other LDL subfractions [45] [46] [47] .
Reverse cholesterol transport
The process of reverse cholesterol transport clears excess cholesterol from the arterial wall through pathways that are mediated by HDL cholesterol 33, 35 (Fig. 1 ).
This process is negatively affected by CKD at several levels. Expression of the ATP-binding cassette (ABC) transporters, ABCA1 and ABCR1, which are key to promoting the efflux of cholesterol from macrophages to lipid-poor HDL precursors 33, 48, 49 , is reduced in CKD 50 .
Activation of the plasma enzyme lecithin-cholesterol

Key points
• An independent, graded inverse relationship exists between cardiovascular risk and estimated glomerular filtration rate (eGFR); patients with end-stage renal disease (eSRD) are at extremely high risk of cardiovascular events.
• In chronic kidney disease (CKD) and eSRD, dysregulation of lipid metabolism results in increased levels of triglycerides and oxidised lipoproteins and reduced levels of HDl cholesterol; lDl cholesterol levels are usually normal.
• As eGFR declines, there is a trend towards smaller relative risk reductions for major vascular events with statin-based therapy with little evidence of benefit in patients on dialysis.
• Deteriorating renal function results in a unique cardiovascular phenotype with an increasing proportion of cardiovascular deaths due to heart failure and arrhythmias, rather than due to atherosclerotic events.
• Several novel therapies are being developed to treat dyslipidaemias and their associated risks; most of these agents are biologics, which are very expensive to produce.
• Currently there is very little evidence to support the use of novel lipid-lowering agents in patients with CKD or eSRD; however, a need exists for further studies of these therapies.
acyltransferase (LCAT) by apolipoprotein AI (ApoAI; the major lipoprotein on HDL) to form cholesterol ester from free cholesterol stimulates the maturation of HDL precursors 33, 51 . Levels of plasma ApoAI and HDL cholesterol are also significantly reduced in patients with CKD as a consequence of reduced liver synthesis of ApoAI and reduced concentration and activity of LCAT 33, [51] [52] [53] . Cholesteryl ester transfer protein (CETP) mediates the transfer of cholesterol ester from HDL particles to triglyceride-rich lipoproteins 40 . Low CETP activity leads to increased plasma HDL cholesterol concentrations and is thought to protect against atheroma formation, although whether HDL cholesterol levels are a modifiable risk factor remains unclear 33, 54, 55 . However, CETP activity is increased in patients with CKD 33, 56, 57 . Impaired HDL cholesterol metabolism in CKD leads to the accumulation of immature HDL particle precursors with limited antioxidative and anti-inflammatory potential 42, [58] [59] [60] . Renal transplant recipients often have high levels of HDL cholesterol but are not protected against atherogenesis, probably as a direct result of the reduced quality of these HDL particles 22, 61 .
Hypertriglyceridaemia
Plasma triglyceride concentrations are increased in the early stages of CKD with the highest levels in patients on dialysis and in those with nephrotic syndrome 42, 62 . The ratio of triglycerides to cholesterol in LDL and HDL particles is also increased in patients with CKD 33 . Hypertriglyceridaemia in CKD results from delayed catabolism of triglyceride-rich lipoproteins, including VLDL particles and chylomicron remnants, coupled to reduced LCAT activity 42, 51 . Lipoprotein lipase (LPL) expression is reduced and the levels of apolipoprotein CIII (ApoCIII), a competitive inhibitor of LPL, are increased in CKD 33, 63 . LPL hydrolyses triglycerides transported within VLDL particles and chylomicrons 64, 65 . Clearance of VLDL particles from the circulation, and their transformation into IDL particles, are also impaired in CKD because of reduced expression of VLDL receptors 
Fig. 1 | Derangements in lipoprotein metabolism in chronic kidney disease. In the endogenous pathway , the liver secretes triglyceride-rich very low density lipoprotein (VLDL) particles that transport triglycerides to peripheral tissues. As triglycerides are hydrolysed by lipoprotein lipase (LPL), the VLDL particles decrease in size to become intermediate density lipoprotein (IDL) particles and finally LDL particles, which retain considerable amounts of cholesterol. The LDL particles transport cholesterol to the liver and peripheral tissues and are cleared by the LDL receptor (LDLR), as well as other specific receptors and scavenger receptors such as scavenger receptor B1 (SR-B1). In the exogenous pathway , triglyceride-rich chylomicrons transport dietary lipids absorbed from the gut. Chylomicrons are catabolized by LPL , resulting in the generation of free fatty acids that are taken up by liver, muscle and adipose tissue. Chylomicrons rapidly diminish in size to become chylomicron remnants that are taken up by the liver via the LDLR . HDL particles have a key role in the process of reverse cholesterol transport, which transports cholesterol from peripheral cells, including macrophages and endothelial cells, to the liver. As renal function declines, a gradual quantitative shift occurs towards a uraemic lipid profile, which is characterized by raised triglycerides, low HDL cholesterol and variable levels of oxidised LDL (ox-LDL) and carbamylated LDL (c-LDL) cholesterol. The lipid profile is also further modified by comorbidities including diabetes mellitus and nephrotic syndrome. In parallel to the quantitative changes, major qualitative changes in the lipoprotein particles that render them more atherogenic also occur, including increased oxidation. ABCA1, ATP-binding cassette transporter A1; ABCG1, ATP-binding cassette transporter G1; ApoAI, apolipoprotein AI; CETP, cholesteryl ester transfer protein; LCAT, lecithin-cholesterol acyltransferase; Lp(a), lipoprotein (a).
Normally defined as a fasting plasma triglyceride level ≥2.3 mmol/l (200 mg/dl).
LDL subfractions
Subfractions of LDL particles are defined based on their size and density; small dense LDL particles are generally associated with high cardiovascular risk.
Atheroma
An abnormal mass of fatty or lipid material with a fibrous covering that exists as a discrete, raised plaque within the intima of an artery.
NATuRe RevIeWS | NEPhROLOGy in adipocytes and myocytes 34, [66] [67] [68] . Glucose loading in patients on peritoneal dialysis 69 and recurrent heparinization in those on haemodialysis are also thought to contribute to this reduced expression 70 . Switching from conventional thrice-weekly 4-hour haemodialysis sessions to more intensive regimens such as nocturnal haemodialysis has been reported to lower triglyceride concentrations and increase HDL cholesterol levels 71 . Attention has focused on alterations of triglyceriderich lipoproteins as predictors of cardiovascular disease 72 .
In the general population, Mendelian randomization analyses support the hypothesis of a causal association between triglyceride and lipoprotein abnormalities, including smaller and denser LDL and HDL particles and cardiovascular disease 72, 73 . Patients with an eGFR <60 ml/ min/1.73 m 2 have a highly prevalent dyslipidaemic phenotype consisting of increased levels of triglyceride-rich lipoproteins that is strongly associated with a high burden of subclinical atherosclerosis 74, 75 and has also been shown to be associated with increased risk of coronary heart disease 76 . In addition, hypertriglyceridaemia is a strong risk factor for cardiovascular events and mortality in patients on haemodialysis with abdominal obesity 77 .
Lipoprotein(a)
Lp(a) is a unique lipoprotein that consists of a central LDL-like core containing a single molecule of apolipoprotein B (ApoB) linked by a disulfide bridge to apolipoprotein(a) 40, 78, 79 . Lp(a) binds to the extracellular matrix and is highly atherogenic 40 . Plasma Lp(a) levels are primarily genetically determined by Lp(a) gene variants and are thought to be causally associated with high cardiovascular risk based on epidemiological, genetic association and Mendelian randomization studies 40, 78, [80] [81] [82] [83] [84] . Interestingly this association seems to become less important once coronary artery disease is established 85 . Elevated Lp(a) levels are also independently associated with the risk of myocardial infarction and death in patients with CKD 86 . The metabolic pathways of Lp(a) production and clearance are not well understood 78 . However, plasma Lp(a) levels seem to increase early in CKD owing to decreased clearance 87 and are increased up to four-fold in patients with nephrotic syndrome 88, 89 . Lp(a) is thought to competitively inhibit fibrinolysis and thus predispose to thrombosis and may also directly promote atherosclerosis 78 . The 2016 ESC/EAS guidelines for the management of dyslipidaemias recommend measuring of ApoB levels as a complementary risk marker, especially in patients with high triglyceride levels, and measuring of Lp(a) levels in selected patients at high risk of cardiovascular disease, in patients with premature cardiovascular disease, and for reclassification in patients with borderline cardiovascular risk 87 .
Oxidative stress
Oxidative stress increases as renal function declines 90 , leading to increased oxidation of circulating lipids 28 . The resulting oxidation products such as oxysterols 91, 92 , malondialdehyde 93, 94 , and oxidized HDL and LDL particles 95, 96 have increased atherogenic potential. Studies of the lipidomic profile in the CKD population show a reduction in phosphatidylcholines, sulfatides and ceramides in LDL particles, as well as an increase in N-acyltaurines 97 . These alterations may contribute to the pro-atherogenic potential of lipoproteins in CKD. Other qualitative abnormalities such as glycosylation and carbamylation have also been reported in patients with CKD 98 . HDL particles in adult and paediatric patients with CKD are modified by retained symmetric dimethylarginine promoting endothelial dysfunction and atherogenesis 99 .
Nephrotic syndrome
Independent of alterations in GFR, increasing levels of albuminuria are associated with dysregulation of lipid metabolism and dyslipidaemia, which is exemplified in patients with nephrotic syndrome 88, 89, 100 . These patients typically have marked hypercholesterolaemia, hypertriglyceridaemia and low-to-normal HDL cholesterol levels. These changes are mediated by changes in the expression and activity of key protein mediators of lipid metabolism, including decreased LPL activity and decreased expression of the LDL receptor 88, 89, 100 , which in part relate to the insulin-resistant state that is observed in these patients. Profound alterations in the structure and function of HDL particles are also present in patients with nephrotic syndrome 89 . Increases in proprotein convertase subtilisin/kexin type 9 (PCSK9) are also thought to contribute to the hypercholesterolaemia that is associated with nephrotic syndrome 88, 101 . However, plasma PCSK9 concentrations do not increase with decreasing GFR, suggesting that PCSK9 does not make a substantial contribution to the dyslipidaemia that is associated with reduced GFR 102 .
Immunosuppressive medication
Kidney transplant recipients and patients with autoimmune or inflammatory conditions, which can be a cause of renal damage or an associated comorbidity, require treatment with immunosuppressive medications, which substantially alter lipid profiles 103 . Calcineurin inhibitors, particularly ciclosporin, increase LDL cholesterol levels by a number of mechanisms, including reduced binding to the LDL receptor, decreased bile acid synthesis and the promotion of glucose intolerance 104, 105 . Although ciclosporin and tacrolimus seem to have similar actions on lipid metabolism and glucose intolerance, the use of ciclosporin is consistently associated with increased levels of LDL cholesterol and ApoB [106] [107] [108] . mTOR inhibitors have anti-atherogenic effects but raise LDL cholesterol levels at least as much as or even more than calcineurin inhibitors by a number of potential mechanisms including inhibition of LPL and increased lipoprotein synthesis 103, [109] [110] [111] . In addition, corticosteroids induce insulin resistance and dose-dependently increase concentrations of circulating cholesterol and triglycerides 103 . The effects of these drugs on dyslipidaemia is additive to that of other immunosuppressive agents.
Lipids and cardiovascular disease
In the general population, a clear linear relationship exists between plasma cholesterol concentration and the risk of coronary heart disease and ischaemic stroke. For every 1 mmol/l (40 mg/dl) increase in LDL cholesterol,
Chylomicron
A lipoprotein with a core of triglycerides surrounded by cholesterol, phospholipids and apolipoproteins that transports dietary fats from the small intestine to tissues after a meal.
Fibrinolysis
The process of enzymatic breakdown of fibrin, mainly by plasmin, that is the usual mechanism for the removal of fibrin clots.
www.nature.com/nrneph the risk of coronary heart disease increases by 40% 112 . However, in patients with ESRD on dialysis, LDL cholesterol has a negative association with all-cause mortality at below average levels and a flat or weakly positive association at higher levels 113, 114 . This relationship, which holds for patients on haemodialysis or peritoneal dialysis and when cardiovascular death is considered as a separate outcome 114 , is often referred to as 'reverse epidemiology' , 'reverse causality' or the 'risk factor paradox' . That is, CKD or an associated comorbidity causes both reduced LDL cholesterol levels and an increased risk of death, thus creating a potentially deceptive association between low LDL cholesterol and mortality 115, 116 . Another possible or complimentary explanation for the inverse relationship between LDL cholesterol levels and all-cause mortality in patients with ESRD is that CKD results in a unique cardiovascular phenotype with fewer deaths due to atherosclerotic processes but more deaths owing to heart failure and sudden cardiac death [117] [118] [119] . The pathophysiology of these conditions seems to be associated with disturbances of calcium and phosphate metabolism, hypertension, arrhythmogenic electrolyte disorders, hypervolaemia, uraemic toxins and anaemia [120] [121] [122] . A specific pattern of myocardial fibrosis that is found in patients with CKD and ESRD, known as cardiomyopathy of CKD or uraemic cardiomyopathy, is thought to form the pathophysiological basis for this phenotype, which is a powerful predictor of cardiovascular mortality in these patients [122] [123] [124] . The hypothesis of a unique cardiovascular phenotype in CKD is supported by a 2018 analysis of the Study of Heart and Renal Protection (SHARP), which included 9,270 patients with moderate to advanced CKD, including 3,015 patients on dialysis 125 . This study found a weak linear relationship between LDL cholesterol levels and the risk of major vascular events (HR 1.14, 95% CI 1.06-1.22 per 0.6 mmol/l increase in LDL cholesterol), whereas the association with non-atherosclerotic events (that is, heart failure and arrhythmias) was inverse (HR 0.90, 95% CI 0.83-0.97 per 0.6 mmol/l increase in LDL cholesterol). These findings suggest that higher LDL cholesterol is indeed associated with increased atherosclerotic events in patients with CKD. Furthermore, studies that do not discriminate between cardiovascular events of different aetiologies when examining the association of CKD with cardiovascular disease could be misleading 126, 127 . Increased HDL cholesterol levels are associated with decreased cardiovascular risk in the general population [128] [129] [130] . However, randomized controlled trials (RCTs) in the general population have not shown significant cardiovascular benefits of increasing HDL cholesterol levels using non-statin medications, including niacin [131] [132] [133] [134] . Low levels of HDL cholesterol are common among patients with CKD and ESRD 135-137 but they do not seem to be associated with increased cardiovascular risk after adjustment for traditional risk factors 138, 139 . Some studies show a J-curve association with increased mortality among patients with ESRD who have very low or very high HDL cholesterol levels [140] [141] [142] . These data further support the importance of renal-function-induced changes in the composition and quality of lipoproteins.
In the general population, hypertriglyceridaemia is an independent cardiovascular risk factor although the association is far weaker than for hypercholesterolaemia 143 . Elevated triglyceride levels are common in patients with CKD and ESRD, especially in those with insulin resistance and diabetes mellitus, and in those who are receiving peritoneal dialysis [144] [145] [146] [147] .
Statin therapy
Beneficial effects of lowering LDL cholesterol levels using 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, commonly known as statins, are well established in patients without renal dysfunction. Their safety and efficacy have been demonstrated in the setting of secondary prevention following an atherosclerotic cardiovascular event in several adequately powered RCTs 148, 149 , and as primary prevention in patients at increased cardiovascular risk such as those with diabetes 150, 151 . The overwhelming nature and magnitude of bene fit of statin therapy in high-risk populations has also been demonstrated in a number of meta-analyses from the Cholesterol Treatment Trialists (CTT) collaboration [152] [153] [154] [155] . Statins might also be beneficial as primary therapy to prevent cardiovascular disease in lower risk populations 155 such as in men with hypercholesterolaemia 156 or in men and women with high levels of high-sensitivity C-reactive protein (hsCRP; a marker of inflammation) in the absence of hyperlipidaemia . To date, all of the large RCTs that have investigated the efficacy of lipid-lowering therapy for the prevention of cardiovascular events in patients with kidney disease have been performed using statins.
Randomized controlled trials
Many of the early RCTs of statin therapy did not focus on renal dysfunction as a cardiovascular risk factor. However, the Pravastatin Pooling Project, which combined the results of three placebo-controlled pravastatin trials, demonstrated that reduced kidney function (eGFR 30-59 ml/min/1.73 m 2 ) was a predictor of cardiovascular events and that lipid lowering was associated with a reduction in the rate of these events in patients with reduced kidney function 158 . Similar results were seen in patients with reduced kidney function (defined as eGFR <60 ml/min/1.73 m 2 ) in the Justification for Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) 159 and Treating to New Targets (TNT) trials 160 .
Kidney transplant recipients.
The first large RCT of statin therapy for the prevention of cardiovascular events in kidney transplant recipients was the Assessment of Lescol in Renal Transplantation (ALERT) study, which included 2,102 kidney transplant recipients receiving ciclosporin-based immunosuppression with stable graft function and total cholesterol levels of 4.0-9.0 mmol/l (155-350 mg/dl) or 4.0-7.0 mmol/l (155-270 mg/dl) if they had previously experienced a myocardial infarction 161 . Patients were randomly assigned to 40 mg fluvastatin or placebo and followed for a mean of 5.1 years. At the end of the study, LDL cholesterol was 1.0 mmol/l (40 mg/dl) lower in the statin group than in the placebo group. Although intervention with fluvastatin failed to reduce the incidence of the combined primary end point of major cardiac events (defined as cardiac death, non-fatal myocardial infarction or coronary intervention), this lipid-lowering therapy was associated with a significant reduction in non-fatal myocardial infarction and cardiac deaths 161 . However, the fairly low number of patients and the lack of a run-in period limited the power of ALERT to detect a difference in outcomes over this time period.
In a complex extension study, all of the ALERT participants were offered open-label, longer-term high dose (80 mg) fluvastatin and followed for a total of 6.7 years 162 . During this period, the benefits of random assignment to the fluvastatin group in the initial study in terms of non-fatal myocardial infarction and cardiac death were sustained. Therefore, the overall conclusion of the study investigators was that statins seem to be safe and efficacious at reducing atherosclerotic cardiovascular events in renal transplant recipients.
Patients with CKD or ESRD. Two large RCTs in patients on dialysis, the Die Deutsche Diabetes Dialyse Studie (4D) 163, 164 and A Study to Evaluate the Use of Rosuvastatin in Subjects on Regular Haemodialysis: An Assessment of Survival and Cardiovascular Events (AURORA) 163, 164 , showed no benefit of statin therapy in patients with ESRD. In the 4D study, 1,255 patients with diabetes who had been on haemodialysis for <2 years (of whom 29% had prior cardiovascular disease) were randomly assigned to receive atorvastatin 20 mg or placebo, with those on a statin undergoing a washout period with placebo for 4 weeks 163, 164 . In the intervention group, LDL cholesterol levels were reduced by a mean of 1.27 mmol/l (49 mg/dl) from a median of 3.13 mmol/l (121 mg/dl) at 4 weeks and remained at this level for the 5-year duration of the study. Despite this decrease, no significant reduction was observed in the incidence of the combined outcome of major cardiovascular events (death from cardiac causes, fatal stroke, non-fatal myocardial infarction and non-fatal stroke) with atorvastatin compared with placebo over a median of 4 years of follow-up (HR 0.92, 95% CI 0.77-1.10). However, atorvastatin therapy did reduce the rate of all cardiac events combined compared with placebo (RR 0.82, 95% CI 0.68-0.99).
In AURORA, 2,776 patients who had been treated with haemodialysis for at least 3 months and were not receiving statin therapy were randomly assigned to rosuvastatin 10 mg daily or placebo 163, 164 . Nearly 40% of patients enrolled in AURORA had known cardiovascular disease of whom 10% had a prior myocardial infarction. The fact that these patients were not on statins at recruitment might illustrate the under-treatment of patients with ESRD even for secondary prevention of cardiovascular disease. In contrast to the 4D study, 74% of the AURORA participants were diabetic; however, only patients over the age of 50 years were recruited whereas the 4D participants were aged over 18 years. Although LDL cholesterol levels in the rosuvastatin group fell by 43% from a mean baseline of 2.6 mmol/l (100 mg/dl), and this reduction was accompanied by a significant decrease in C-reactive protein levels, no significant reduction was observed in the incidence of major cardiac events with rosuvastatin compared to placebo after a median follow up of 3.8 years (HR 0.96 95% CI 0.84-1.11). However, the combined primary end point in AURORA was not specific and included non-atherosclerotic events.
Importantly, patients enrolled in 4D and AURORA were not selected on the basis of hypercholesterolaemia. Although patients with an LDL cholesterol level >4.9 mmol/l (190 mg/dl) were excluded from the 4D trial 164 , atorvastatin therapy significantly reduced the risk of fatal and non-fatal cardiac events in participants with a pretreatment LDL cholesterol level >3.76 mmol/l (>145 mg/dl) 165 . However, such subanalyses of RCTs should be interpreted with caution because of the combination of reduced statistical power, increased variance and the play of chance [166] [167] [168] . The double-blind, randomized SHARP trial tested the effect of lipid lowering with simvastatin plus ezetimibe for primary prevention of atherosclerotic vascular events in 9,270 patients with CKD 169 . At enrolment, 6,247 of these patients had a serum creatinine level greater than 150 μmol/l (1.7 mg/dl) for men or greater than 130 μmol/l (1.5 mg/dl) for women and did not require dialysis; the remaining 3,023 patients were on dialysis 169 . Of note, about 30% of the study population had stage 4 CKD and 13% were already at Stage 5 CKD but not on dialysis; thus, 75% of the study population had stage 4 or stage 5 CKD. On enrolment, the SHARP participants were initially randomly assigned to simvastatin plus ezetimibe, simvastatin alone and placebo groups. After 1 year, those who were initially allocated to simvastatin alone were randomly reassigned to receive either simvastatin plus ezetimibe or placebo. Lipid lowering with simvastatin 20 mg combined with ezetimibe 10 mg led to a mean difference in LDL cholesterol levels of 0.85 mmol/l (33.0 mg/dl) compared to placebo. After an average of 4.9 years of follow-up, a significant reduction in major atherosclerotic events was observed in the simvastatin plus ezetimibe group (HR 0.83, 95% CI 0.74-0.94).
The cardiovascular events in SHARP were more tightly defined than in 4D or AURORA, specifically focusing on thrombo-occlusive disease that would be modifiable with lipid-lowering therapy. Thus the primary outcome was a composite of major atherosclerotic events (coronary death, myocardial infarction, non-haemorrhagic stroke or any revascularization). The effect of lipid-lowering treatment was not associated with a significant reduction in these events when only those patients who were on dialysis at enrolment were considered (HR 0.90, 95% CI 0.75-1.08). However, SHARP was not powered to detect a benefit in this patient group. After weighting for subgroup-specific reductions in LDL cholesterol levels, the effects of LDL cholesterol lowering on outcomes in patients on dialysis did not differ from those in patients with non-dialysed CKD (χ 2 = 1.34; P = 0.25). The SHARP study clearly demonstrates a benefit of lowering LDL cholesterol levels in patients with CKD not requiring dialysis, which is in keeping with the association of these levels with cardiovascular disease www.nature.com/nrneph in this population 125, 170 . Notably, a post hoc analysis of the SHARP data showed that lowering of LDL cholesterol was not associated with any delay in progression of CKD 171 . This finding is in line with the results of a subsequent meta-analysis 172 . Despite the differences in study populations and interventions between the 4D, AURORA and SHARP studies, the apparent lack of efficacy of statins for prevention of cardiovascular events in patients on dialysis was remarkably similar. Several potential explanations for this failure exist. First, LDL cholesterol is not associated with cardiovascular disease in patients on dialysis. However, such a lack of association seems unlikely given the well-established direct causal relationship between LDL cholesterol and atheroma 153, 155 . Second, cardiovascular events in patients on dialysis are proportionally increased due to non-atheromatous processes such as sudden death and heart failure, which would not necessarily be directly improved by lowering of LDL cholesterol levels 117, 118 . Third, all three studies had relatively small numbers of patients on dialysis compared with other studies of lipid-lowering therapies (for example, the Scandinavian Simvastatin Survival Study (n = 4,444) 148 and the West of Scotland Coronary Prevention Study (n = 6,595) 156 ) and could therefore have been underpowered to detect a modest effect.
Adverse effects. In the very large RCTs conducted to date, the only serious adverse events that have been reported with long-term statin treatment are myopathy (defined as muscle pain and/or weakness in conjunction with substantially raised serum creatine kinase levels), new-onset diabetes mellitus and possibly haemorrhagic stroke 154 . Treating 10,000 patients for 5 years with an effective statin (for example, atorvastatin 40 mg) would cause five cases of myopathy, with one case progressing to full-blown rhabdomyolysis if the statin was not discontinued, 50-100 cases of muscle pain and weakness that do not meet the criteria for myopathy, 50-100 cases of diabetes mellitus and 5-10 haemorrhagic strokes 154 . The findings of large placebo-controlled RCTs suggest that most of these adverse effects are not directly attributable to the statin treatment 154 . However, controversy persists regarding how well data on adverse effects have been collected 173 .
Meta-analyses
Meta-analyses have shown that the proportional reduction in LDL cholesterol levels achieved during statin trials in the general population is directly associated with the proportional reduction in risk of major vascular events 152 . In these studies, a 1 mmol/l reduction in LDL cholesterol is associated with a 22-23% reduction in these events 152 . Although observational data have important limitations, especially with regard to confounding and bias 154 , this reduction is approximately half that predicted from the observational relationship (40% would be expected) 112 . This finding is perhaps not particularly surprising. In most of the statin trials patients were treated for around 5 years whereas exposure to LDL cholesterol in epidemiological studies lasts a lifetime. However, the relationship seems to be modified in patients with CKD, suggesting that the worse the renal function, the lower the cardiovascular risk reduction per reduction in LDL cholesterol levels 119, 174 , with no risk reduction being demonstrable in patients on dialysis 119 . In general, statins tend to increase circulating levels of Lp(a) and these may contribute to residual cardiovascular risk despite lowering of LDL cholesterol levels 175 . As discussed above, circulating concentrations of Lp(a) increase with declining renal function and are highest in patients on dialysis 176 . Whether this finding explains the reduced cardiovascular benefit of LDL lowering in patients with CKD compared with the general population remains to be determined 176 .
A number of meta-analyses have pooled data from trials in patients with varying degrees of CKD and ESRD to study the effect of lipid lowering with statins and/or lowering of LDL cholesterol using ezetimibe in these populations [177] [178] [179] [180] [181] [182] . The consistent finding of the individual trials is that lowering of LDL cholesterol is beneficial for prevention of major atherosclerotic events in patients not requiring dialysis (including kidney transplant recipients), whereas lipid lowering has no obvious benefit in patients on dialysis. However, the findings of the meta-analyses are somewhat conflicting [177] [178] [179] [180] [181] [182] . The most comprehensive of these meta-analyses, which was conducted by the CTT collaboration, analysed data from 28 trials of statin-based therapy in patients with various degrees of renal impairment and included readjudication of all deaths in the AURORA trial to align with atherosclerotic end points in the trials conducted in patients on dialysis 119 . This meta-analysis demonstrated that as eGFR declines there is a trend towards smaller relative risk reductions for major coronary events and stroke with statin therapy, even after adjusting for smaller reductions in LDL cholesterol levels in patients with more severe CKD. In particular, there was little evidence that statin-based therapy reduced cardiovascular events in patients who were already on dialysis 119 . However, despite the reduced relative benefit of statin-based cholesterol lowering in ESRD, an absolute benefit may persist as the total number of atherosclerotic events in this population is extremely high, especially in high-risk patients such as those with concomitant diabetes mellitus 12, 119 . Indeed, a subanalysis of the 4D study showed that atorvastatin treatment significantly lowered the risk of fatal and nonfatal cardiac events in patients with type 2 diabetes on haemodialysis with pretreatment LDL cholesterol levels >3.76 mmol/l (>145 mg/dl) 165 . However, as always, the result of this secondary analysis should be interpreted with caution.
Anti-inflammatory effects
Inflammation has been implicated in the pathophysiology of cardiovascular disease in the general population and in patients with CKD and ESRD 183, 184 . A chronic inflammatory state is observed in these patients owing to factors including decreased clearance of proinfla mmatory cytokines, increased oxidative stress, acidosis, infections and the dialysis procedure [185] [186] [187] [188] . Therefore, targeting inflammation, either directly or indirectly, might improve outcomes independently of lipid lowering in patients with CKD or ESRD.
Several lines of evidence support an anti-inflam matory action of statins 189 . Moreover, the JUPITER trial showed that potent statin therapy reduced the risk of major cardio vascular events by 44% in patients with elevated levels of hsCRP (>2 mg/l (19 nmol/l)) and LDL cholesterol levels <3.37 mmol/l (130 mg/ml) 157, 190 . Similar reductions in cardiovascular risk were found in a secondary analysis of the 3,267 JUPITER parti cipants who had an eGFR <60 ml/min/1.73 m 2 (reF. 191 ). Of note, patients with a creatinine level >177 μmol/l (>2 mg/dl) were excluded from the JUPITER trial.
A subanalysis of the SHARP trial showed that although higher baseline hsCRP levels were associated with an increased risk of major cardiovascular events, the reduction in cardiovascular risk in those who received combination therapy with simvastatin and ezetimibe was similar irrespective of baseline hsCRP 125 . Although this result should be interpreted with caution, it suggests that the simvastatin and ezetimibe combination reduces cardiovascular risk independently of the presence of inflammation.
Fibrates
RCTs have shown that lowering triglyceride levels with fibrate monotherapy decreases cardiovascular risk in the general population, although this benefit may be limited to individuals with very high triglyceride and very low HDL cholesterol levels 4, [192] [193] [194] . However, the use of fibrates, although possibly not gemfibrozil 195 , to lower triglyceride levels may increase creatinine levels, especially in patients with eGFR <30 ml/min/1.73 m 2 , by mechanisms that are not fully elucidated 4, 24, [196] [197] [198] [199] . Currently very little evidence exists to recommend the use of fibrates in patients with CKD unless triglyceride levels are very high (>11.3 mmol/l (>1,000 mg/dl)), in which case these therapies should be used judiciously and dose adjusted for renal function 1 .
Bile acid sequestrants
Bile acid sequestrants (anion exchange resins) were developed in the 1970s as cholesterol-lowering agents 200 . They bind gut bile acids and reduce enterohepatic recirculation, indirectly leading to reductions in intestinal cholesterol absorption and circulating LDL cholesterol levels 201, 202 . Monotherapy with bile acid sequestrants dosedependently lowers plasma LDL cholesterol by 10-28%, with little effect on HDL cholesterol 202, 203 . However, bile acid sequestrants do modestly increase circulating triglyceride concentrations 204 . Bile acid sequestrants (for example, cholestyramine, colestipol and colesevelam) are currently recommended as second-line options in patients with atherosclerotic cardiovascular disease 87, 205 . However, a 2018 meta-analysis was unable to identify any RCTs of bile acid sequestrants conducted with more than 500 patients and >1 year follow-up 206 . Although these medications are generally safe because they are not systemically absorbed, the fact that they can lead to an increase in circulating triglycerides may limit their utility in patients with hypertriglyceridaemia, including patients with CKD or ESRD 207 . Moreover, bile acid sequestrants have not been well studied in patients with CKD or ESRD and very little evidence exists to support their use in these populations.
Omega-3 fatty acids Pharmacological doses (2-4 g per day) of omega-3 fatty acids (eicosapentaenoic acid and docosahexaenoic acid) reduce triglyceride levels by up to 45% in a dosedependent manner but have little to no effect on levels of LDL cholesterol or HDL cholesterol in the general population or in patients with CKD or ESRD [208] [209] [210] [211] [212] [213] [214] [215] [216] . The mechanisms of action of omega-3 fatty acids are poorly understood and several pathways could be involved, including reduced hepatic VLDL triglyceride synthesis and/or secretion, enhanced triglyceride clearance from circulating VLDL particles, decreased hepatic lipogenesis and increased plasma LPL activity 217, 218 . 221, 222 . To date, REDUCE-IT 221 and STRENGTH 222 have recruited 8,000 and 13,086 patients, respectively. REDUCE-IT excludes patients on dialysis and those with a creatinine clearance <30 ml/ min, whereas STRENGTH excludes patients on dialysis but considers microalbuminuria (albumin:creatinine ratio >30 mg/g) and an eGFR of <45 ml/min/1.73 m 2 to be criteria for a high risk of future cardiovascular events, which is a study entry requirement.
Emerging lipid-lowering therapies Treatment of dyslipidaemia with the most widely used lipid-lowering drugs provides a substantial reduction in cardiovascular risk. However, a proportion of treated patients will continue to have cardiovascular events 40, 223 . Several novel therapies for the treatment of dyslipidaemias and their associated risks are being developed. These therapies include agents that target major mediators of the clearance and secretion of atherogenic proteins (TAbLe 1) .
PCSK9 inhibitors
PCSK9 is a secreted serine protease that binds to the extracellular domain of the hepatocyte LDL-receptor and promotes its lysosomal degradation. This receptor degradation reduces LDL particle uptake and leads to increased concentrations of circulating LDL cholesterol 224, 225 (Fig. 2) . In 2003, gain-of-function mutations in the gene encoding PCSK9 (reF. 226 ) were reported to cause autosomal dominant hypercholesterolaemia 227 . Subsequently, loss-of-function mutations in PCSK9 were discovered to reduce LDL cholesterol levels by 15-28% and the risk of coronary heart disease by 47-88% [228] [229] [230] [231] . Monoclonal antibodies that act as PCSK9 inhibitors sequester PCSK9 and thereby prevent LDL receptor catabolism, leading to an increase in LDL receptor density on hepatocytes 26, 232 . The efficacy of one such antibody, alirocumab, has been investigated in the Effect 40, [233] [234] [235] [236] [237] [238] [239] [240] [241] [242] [243] . Overall, these trials showed that alirocumab therapy reduced LDL cholesterol levels by 36-61% after a minimum of 24 weeks of treatment 40, [233] [234] [235] [236] [237] [238] [239] [240] [241] [242] [243] . Alirocumab also consistently reduced concentrations of total cholesterol, ApoB, non-HDL cholesterol and Lp(a) independently of statin treatment and of additional ezetimibe use in populations with heterozygous familial hypercholesterolaemia or non-familial hypercholesterolaemia 244 . A post hoc analysis of the Long-term Safety and Tolerability of Alirocumab in High Cardiovascular Risk Patients with Hypercholesterolemia Not Adequately Controlled with Their Lipid Modifying Therapy (ODYSSEY LONG TERM) study showed a 52% reduction in major cardiovascular events after alirocumab treatment in patients with heterozygous familial 246 ). Among the patients with CKD, 315 were randomly assigned to alirocumab and 99% were already receiving a statin. The reduction in LDL cholesterol levels at week 24 in patients with CKD treated with alirocumab ranged from 46.1% to 62.2% with an efficacy and safety profile comparable to that of patients with normal renal function (eGFR >60 ml/min/1.73 m 2 ). The ODYSSEY OUTCOMES trial included 18,924 participants who had experienced an acute coronary event 1-12 months before enrolment 247 . Following a runin phase of 2-16 weeks on high intensity statin therapy, these participants were randomly assigned to fortnightly alicorumab treatment or placebo groups. The alicorumab therapy was titrated to keep LDL cholesterol levels between 0.65 mmol/l and 1.3 mmol/l (25-50 mg/dl). In this trial, alicorumab therapy resulted in a significant reduction in the primary outcome of major cardiac events (HR 0.85; 95% CI 0.78-0.93; P = 0.0003) [247] [248] [249] . Patients with an eGFR <30 ml/min/ 1.73 m 2 were excluded from this trial. The efficacy of another PCSK9 inhibitor, evolocumab, is being assessed in the Program to Reduce LDL cholesterol and Cardiovascular Outcomes Following Inhibition of PCSK9 in Different Populations (PROFICIO) [250] [251] [252] [253] [254] . This program of 14 phase III clinical trials aims to recruit approximately 30,000 patients. So far, studies have ranged from 10 to 52 weeks in duration and have included patients treated either with evolocumab monotherapy or with evolocumab in combination with a statin or ezetimibe. Significant reductions in LDL cholesterol levels have been reported, ranging from 49% to 65%, with substantial reductions in the levels of non-HDL cholesterol, ApoB and Lp(a), and modest effects on triglycerides and HDL cholesterol. In addition, coronary atheroma regression with evolocumab compared with placebo (-0.95% versus +0.05%) has been reported in a double-blind, placebo-controlled trial in 968 patients with proven coronary atheroma on angiography that used serial intravascular ultrasound to assess atheroma volume 255 . A greater proportion of patients in the evolocumab group than in the placebo group also had plaque regression in this trial (64.3% versus 47.3%) 255 . The Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) trial included 27,550 patients with known atherosclerotic vascular disease (previous myocardial infarction, non-haemorrhagic stroke or symptomatic peripheral vascular disease), LDL cholesterol >1.8 mmol/l (>70 mg/dl) or non-HDL cholesterol >2.6 mmol/l (>100 mg/dl) already on optimized statin therapy 256 . This study reported a significant reduction in the primary outcome (composite of cardiovascular death, myocardial infarction, stroke, hospital admission for unstable angina or coronary revascularization) with evolocumab therapy (9.8%) compared with placebo (11.3%; HR 0.85, 95% CI 0.79-0.92) 256 . Although patients with an eGFR >20 ml/min/1.73 m 2 were eligible for inclusion in FOURIER 257 , no information on the number of patients with CKD who were enrolled and the outcomes in this population is currently available.
The safety and efficacy of another monoclonal antibody, bococizumab, in patients at high cardiovascular risk was investigated in the Studies of PCSK9 Inhibition and the Reduction of Vascular Events (SPIRE) 1 and SPIRE 2 (reF. 258 ) After 12 weeks of treatment, bococizumab given fortnightly lowered circulating LDL cholesterol levels in a dose-dependent manner, with the highest dose of 150 mg achieving a 52% reduction 258 . Four-weekly dosing of bococizumab also reduced LDL cholesterol in a dose-dependent manner with the highest dose of 300 mg achieving a 33% reduction 258 . However, further clinical development of this agent has been stopped because of an unexpected decrease in LDL cholesterol lowering over time, high levels of immunogenicity and high rates of injection-site reactions 40 . Unlike treatment with therapeutic antibodies, which bind to and inhibit their target protein, treatment with short-interfering RNAs (siRNAs) results in the destruction of the target messenger RNA and reduces the production of the protein 259 . Inclisiran (ALN-PCSSC) is a fully chemically modified siRNA conjugated to triantennary N-acetylgalactosamine that inhibits the synthesis of PCSK9 (reF. 260 ). In a phase I trial in healthy volunteers with a LDL cholesterol level >2.59 mmol/l (100 mg/dl), a single dose of inclisiran >100 mg lowered LDL cholesterol levels by a mean of 50.6% from baseline with reductions maintained for up to 6 months in those who received doses >300 mg (reF.
261
).
In a phase II multicentre study (ORION-1), 501 patie nts at high cardiovascular risk with elevated LDL As pH decreases inside the endosome, the LDLR dissociates from this complex. LDL cholesterol is incorporated into the cell and the LDLR recycles to the cell surface. b | Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an extracellular protein that binds directly to the LDLR and induces its internalization and degradation. Therapeutic agents that target PCSK9 either reduce the synthesis of the protein or block its binding to the LDLR . These agents prevent degradation of the LDLR, thereby preserving LDLR recycling, which increases LDLR density on the hepatocyte surface and therefore enables more LDL cholesterol to be removed from the circulation.
www.nature.com/nrneph chol esterol levels received two doses of inclisiran (300 mg) at day 0 and day 90 (reF.
262
). This regimen reduced LDL chol esterol levels by 52.6%, with 48% of patients having an LDL cholesterol concentration <0.04 mmol/l (1.5 mg/dl) at 180 days. Sustained reductions in the levels of ApoB, non-HDL cholesterol, VLDL cholesterol and triglyceride as well as modest increases in HDL cholesterol and ApoAI were also reported 263 . The magnitude of these changes was broadly comparable to that observed in trials of PCSK9-inhibiting monoclonal antibodies 263 . Although preliminary, these results raise the possibility of lowering cholesterol levels using twice yearly injections. This possibility is being investigated in an extension study of ORION-1, which involves a head-to-head comparison between inclisiran 300 mg every 180 days and fortnightly evolucamab (ORION-3) 
264
. Ongoing trials are also investigating the safety and efficacy of inclisiran in patients with familial hypercholesterolaemia (ORION-2) 265 and in patients with atherosclerotic cardiovascular disease 266, 267 . In addition, an open-label, single-dose study of 300 mg inclisiran is planned in 24 patients with renal impairment and creatine clearance as low as 15 ml/min (ORION-7)
268
.
CETP inhibitors
As mentioned above, CETP mediates the exchange of cholesteryl esters and triglycerides between mature HDLs and triglyceride-rich ApoB-containing lipoproteins and LDLs, thus modifying the lipid composition of HDLs 40 (Fig. 3) . The first CETP inhibitor tested in humans, torcetrapib, increased HDL cholesterol levels by 72% and decreased LDL cholesterol levels by 25% 131, 269 . However, these positive changes in the lipid profile were associated with an increased risk of cardiovascular events and mortality, probably through CETPindependent actions on blood pressure and circulating levels of aldosterone and endothelin 1 131, 270 . The development of the CETP inhibitors evacetrapib and dalcetrapib was halted because of a lack of beneficial effects on cardiovascular events despite improvement of the lipid profile (more than a doubling of HDL cholesterol and a 30% decrease in LDL cholesterol levels) in patients post-acute coronary syndrome and at high cardiovascular risk 40, 133, 271, 272 . Another CETP inhibitor, anacetrapib, increased HDL cholesterol by 138% and reduced LDL cholesterol by 30% and Lp(a) by 39% in high-risk patients on statin therapy 273 . The phase III Randomized Evaluation of the Effects of Anacetrapib Through Lipid-Modification (REVEAL) trial in patients with pre-existing atherosclerotic vascular disease who were already on an effective LDL cholesterol lowering regimen (mean LDL cholesterol at randomization of 1.6 mmol/l (61 mg/dl)) showed a statistically significant decrease in major coronary events of 9% (HR 0.91, 95% CI 0.85-0.97) in the intervention group compared with the placebo group 274, 275 . Unfortunately, patients with CKD and a serum creatinine level >200 μmol/l (>2.3 mg/dl) or with ESRD were excluded from this study. However, no benefit of anacetrapib was observed in the subgroup of patients with an eGFR <60 ml/min/1.73 m 2 or macroalbuminuria, although the number of these patients was small and there was no significant heterogeneity with respect to other groups.
Interestingly, the beneficial effects of anacetrapib seem to be the result of lowering non-HDL cholesterol levels, rather than increasing HDL cholesterol 272 . Anacetrapib is unlikely to become a licensed drug because the manufacturer has stopped development and at present will not be filing for approval. Clinical development of the CETP inhibitor obicetrapib was also halted in view of the REVEAL trial results, despite data from a phase II RCT showing that this agent increased HDL cholesterol levels by >160% and decreased LDL cholesterol levels by 47% 276 . These results of clinical trials with CETP inhibitors are perhaps not surprising. Some have suggested that the rise in HDL cholesterol that is caused by administration of these agents is not solely due to enhanced reverse cholesterol transport 277, 278 . Instead this effect is caused by blockade of the exchange of the cholesterol cargoes of HDL particles with the triglyceride cargo of IDL particles. This process is essential to transform oxidationprone, pro-inflammatory and atherogenic IDL particles and triglyceride-rich LDL particles into cholesterolester-rich LDL particles, which are removed from the circulation by liver LDL receptors 277, 278 (Fig. 1) . 40, 280 . IONIS-APO(a) (previously called ISIS 681257) is an antisense oligonucleotide targeting the Lp(a) gene that was shown to be safe and to decrease plasma Lp(a) levels by up to 80% in a phase I RCT 281 . Phase II RCTs with IONIS-APO(a) and IONIS-APO(a)-I, a ligand conjugated antisense oligonucleotide variant, have shown reductions in plasma Lp(a) of up to 96% in two cohorts of patients with Lp(a) 125-437 nmol/l and >438 nmol/l, respectively 282 . Currently no data are available on clinical outcomes using these agents.
Inhibitors of VLDL production
Inhibition of VLDL particle production decreases the levels of the downstream LDL particle 40 . Lomitapide inhibits microsomal triglyceride transfer protein (MTTP) 283 , which assembles lipids with ApoB to form lipoproteins, and mipomersen is an antisense agent that inhibits the synthesis of ApoB [284] [285] [286] . However, both agents may cause liver steatosis and are currently only in use as adjunct therapy in homozygous familial hypercholesterolemia 40, [287] [288] [289] [290] . No data are available on cardiovascular outcomes with either lomitapide or mipomersen 291, 292 .
ApoCIII antisense oligonucleotide
Increased levels of ApoCIII and the presence of ApoCII in ApoB-containing liposomes, ApoA-containing lipoproteins and Lp(a) are associated with increased atherogenic risk 293, 294 . Potential mechanisms for this increased atherogenicity include inhibition of LPL activity 64, 295 , promotion of hepatic VLDL secretion 296, 297 and decreased hepatic clearance of triglyceride-rich lipoproteins 293 . An ApoCIII gene antisense oligonucleotide, volanesorsen, has been shown to decrease serum triglyceride levels and the incidence of pancreatitis in patients with familial chylomicronaemia syndrome (FCS) 294, 298 . Additional studies of volanesorsen are ongoing in patients with hypertriglyceridaemia and other populations 298 .
Anti-ANGPTL3 antibody
Angiopoietin-related proteins (ANGPTL) are important regulators of lipid metabolism 299 , and ANGPTL3 is an endogenous inhibitor of LPL. Loss-of-function mutations of ANGPTL3 are associated with decreased LDL chol esterol and triglyceride concentrations 299 . In healthy volunteers, the anti-ANGPTL3 antibody evinacumab reduced triglyceride levels by up to 76% and LDL cholesterol by up to 23% 299 with similar reductions observed with the antisense oligonucleotide ANGPTL3-L Rx (63% and 33%, respectively) 300 .
HDL peptide mimetics
HDL peptide mimetics are parenteral drugs that mimic the structural and functional properties of HDL precursors and stimulate reverse cholesterol transport 40, 301 . In a phase IIb RCT, the plasma-derived ApoAI peptide CSL112 increased ApoAI levels and ex vivo cholesterol efflux in patients who had experienced myocardial infarction in the week before enrolment but did not modify the incidence of major atherosclerotic events (a secondary end point) 302 . A phase II study of CSL112 in 83 patients with CKD stage 3 and previous myocardial infarction is ongoing 268 ; a phase III, multicentre, double-blind, placebo-controlled RCT in 17,400 patients with acute coronary syndromes started recruitment in March 2018 (reF.
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CER-001 consists of recombinant human ApoAI complexed with phospholipids that mimic HDL precursors 304 . A phase II RCT failed to show any effect of CER-001 on plaque regression compared with placebo in 507 patients with post-acute coronary syndrome 305 . However, a subsequent analysis of the trial data by a second core laboratory did demonstrate reductions in total atheroma volume at the highest dose (3 mg/kg) of CER-001 in patients with the greatest plaque burden at baseline compared with placebo 306, 307 . However, a subsequent double-blind, placebo-controlled RCT failed to show any regression of atherosclerotic plaque using 10 weekly infusions of CER-001 at a dose of 3 mg/kg in patients with high plaque burden who had experienced acute coronary syndrome 308 . Further development of CER-001 is currently uncertain 309 .
Other agents
Several other novel lipid-lowering agents with potential future relevance to patients with CKD or ESRD are in various stages of development (TAbLe 1) .
ATP-citrate synthase inhibitors.
A potential therapeutic target is the critical enzyme ATP-citrate synthase, which links glucose catabolism to lipogenesis by producing acetyl-coenzyme A (acetyl-CoA) from mitochondrial citrate for fatty acid and cholesterol synthesis 310, 311 . Bempedoic acid is a potent inhibitor of ATP-citrate synthase 312 that has been shown to prevent dyslipidaemia and attenuate atherosclerosis in animal models [312] [313] [314] [315] . In phase II RCTs in patients with hypercholesterolaemia, bempedoic acid lowered LDL cholesterol levels by up to 43% when used as a monotherapy 316, 317 , by up to 48% when used in combination with ezetimibe 318 , by up to 24% in patients who were already receiving statin therapy 319 , and by 28.7% in patients with statin intolerance 320 .
Acetyl-CoA carboxylase inhibitors. Gemcabene is a dialkyl ether that reduces hepatic synthesis of triglycerides and cholesterol by a number of pleiotropic actions, including inhibition of acetyl-CoA, and enhances the clearance of VLDL particles upstream of LDL production 40, 321, 322 . In patients with low HDL cholesterol levels, normal LDL cholesterol levels and hypertriglyceridaemia who were not receiving any other lipid-lowering therapy, gemcabene treatment lowered LDL cholesterol and serum triglycerides and increased HDL cholesterol 323 . In patients with hypercholesterolaemia who were already on a statin, gemcabene lowered LDL cholesterol levels by 24% 321 .
www.nature.com/nrneph DGAT1 inhibitors. Diacylglycerol O-acyltransferase 1 (DGAT1) catalyses the final step in triglyceride synthesis. This key enzyme for the absorption of dietary fat is highly expressed in enterocytes 324 . In short-term studies, the DGAT1 inhibitor pradigastat lowered postprandial plasma triglyceride levels in a dose-dependent manner by up to 90% 325 . In patients with FCS, pradigastat lowered fasting and postprandial plasma triglyceride levels by 70% 324 .
Implications for health economics
In 2009, the health-care cost associated with cardiovascular disease across the European Union was €106 billion, approximately 9% of the total health-care outlay 87 . Most cost-effectiveness studies of cardiovascular disease prevention combine research data and simulation models 87, 154, [326] [327] [328] [329] [330] , and estimates of cost-effectiveness can vary hugely depending on the assumptions made with regards to some basic parameters, especially the age and cardiovascular risk of the target population and the cost of the intervention 87 . Therefore, results for one condition or country will not necessarily be applicable to other situations. The incidence of serious adverse events can also have a major impact on cost-effectiveness 154 , as can the availability of generic drugs 331 . Despite the adverse effects discussed above, the cost-effectiveness of statin therapy for the prevention of cardiovascular events in the general population is well established and the benefits persist in the long-term 154 . Moreover, for each year statin therapy is prolonged, larger absolute benefits accrue 154 . In patients with CKD, the evidence supporting the cost-effectiveness of statin therapy is limited. However, studies from the US and UK suggest comparable cost-effectiveness of statins for prevention of cardiovascular events in the general population and in patients with CKD not on dialysis 328, 332 . Given the increased cardiovascular risk that is associated with CKD and the mollified effect of LDL cholesterol reduction on cardiovascular events in patients with reduced renal function 1 , treatment with novel lipidmodifying drugs might be an attractive option for physicians and their patients. Such a preference could be a matter of concern for health-care providers given the currently excessive costs of these new agents [333] [334] [335] . The issue of safety also needs to be addressed. The medical community as a whole, and the field of nephrology in particular, has previously fallen into the trap of extrapolating data from basic science, observational studies or clinical studies in other populations to justify treatments in patients with CKD that have eventually been shown to not be beneficial or even be damaging in later RCTs in this population [336] [337] [338] [339] [340] [341] . As any investment in a new therapy reduces the resources that are available for other therapies 342 , lipidmodifying agents should be evaluated carefully for their health-economic impact as well as for their safety in patients with CKD 21 . In the past, patients with severe CKD (stage 4 or higher) were routinely excluded from cardiovascular trials 343 . However, pressure should be put on regulatory and licensing authorities to demand the inclusion of patients with CKD in these trials in the future. Similar approaches together with several incentives have already improved the recruitment of women, children, elderly people and ethnic minorities into RCTs [344] [345] [346] . The importance of lifestyle modification, including adhering to a healthy diet, regular exercise, smoking cessation and maintaining a healthy weight is emphasized by many guidelines aimed at lowering cardiovascular risk in the general population, both before and after the use of lipid-lowering treatment [3] [4] [5] 9, 10, 87 . However, such modifications remain an underexploited healtheconomic resource 21 . In Germany, societal costs from non-communicable diseases including CKD might decrease by €168 (£149; US$207) billion per year if the population reduces their dietary intake of salt, sugar and saturated fat to recommended levels 347 . The idea of imposing a 'fat tax' or 'health tax' is controversial but might lead to a modification of dietary habits 348 and decrease societal costs of non-communicable diseases 349 . In addition, the income raised by such a tax could be reinvested in health. Careful attention to health-economic aspects should become an essential part of medical and political decision making, including regarding lipid lowering in CKD 21 .
The KDIGO Clinical Practice Guideline
The 2013 KDIGO Clinical Practice Guideline for Lipid Management in CKD 1 has caused extensive discussion and controversy [350] [351] [352] . Similar to all KDIGO guidelines published to date, production of the lipid management guideline involved a thorough and rigorous process. Notably, the document makes recommendations for treatment but is not a rigid set of instructions. This point is especially important given that several of the recommendations were based on weak evidence. Although the summary recommendations can be interpreted as being very rigid, the guideline document puts these recommendations into context with plenty of room for personalization for individual patients. This context is critical given that guidelines as a whole tend to be simplifications, which makes them easier to remember and implement but can result in the misclassification of individual patients 353, 354 . In the 5 years since the publication of the KDIGO guideline, new clinical data have become available, novel therapies have emerged and other lipid management guidelines have been published. The KDIGO guideline deserves consideration and comment in light of these developments (TAbLe 2) .
Assessment of lipid status
The KDIGO guideline recommends assessment of a lipid profile consisting of total cholesterol, LDL cholesterol, HDL cholesterol and triglycerides but does not recommend measurement of Lp(a), ApoB and other lipid markers 1 . As discussed above, emerging evidence suggests that these biomarkers might have utility in risk prediction and stratification in the general population, and several subsequently published guidelines recommend their measurement 4, 87 . However, their usefulness for risk prediction in patients with CKD remains to be established.
Perhaps most controversially 350, 351 , the KDIGO guideline does not recommend follow-up measurement of lipid levels for the majority of patients. The evidence level for this statement is 'not-graded' , and the recommendation is based on the lack of data on treatment escalation to achieve specific LDL cholesterol targets, substantial within-person variability in LDL cholesterol measurements and the increased potential for medication toxicity in patients with CKD [355] [356] [357] . However, other reasons for follow-up measurements might exist, including monitoring or incentivizing adherence to treatment, which is known to be low in patients with CKD 358 , change in renal replacement modality or concerns about the presence of new secondary causes of dyslipidaemia 1 
.
Other guidelines do suggest target cholesterol reductions 4, 87 . The reasons for this difference are complex. Only taking into account evidence from RCTs ignores the totality of the available evidence and therefore restricts the potential to prevent cardiovascular disease. Systematic reviews have repeatedly confirmed a dosedependent reduction in cardiovascular events with lowering of LDL cholesterol levels; that is, the greater the reduction in LDL cholesterol, the greater the reduction in cardiovascular risk 153, 155 . The benefits of reducing LDL cholesterol do not seem to be restricted to statin treatment 359 . In addition, no level of LDL cholesterol below which further reduction is not associated with benefit or results in harmful effects has ever been defined. Furthermore, considerable variability exists in the reduction in LDL cholesterol levels that is achieved with therapy 360 . These factors support a tailored individualized approach to treatment with the setting of goals to assist doctor-patient communication and potentially enhance adherence. Such an approach is particularly relevant to patients who are considered to be at very high cardiovascular risk, such as those with advanced CKD or ESRD, those who have recently experienced 
Triglyceride-lowering treatment
In adults with CKD (including those treated with chronic dialysis or kidney transplantation) and hypertriglyceridaemia, we suggest that therapeutic lifestyle changes be advised
No new evidence to suggest that a revision is potentially required a The Kidney Disease: Improving Global Outcomes (KDIGO) recommendations are graded according to the quality of the evidence on which they are based. Please see the original publication 1 for details. CKD, chronic kidney disease; GFR , glomerular filtration rate.
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an acute cardiovascular event and those with genetic disorders of cholesterol metabolism and significant hypercholesterolaemia in whom statins are indicated.
Cholesterol-lowering treatment
The KDIGO guideline recommends that patients with CKD stages 3-5 (not on dialysis) aged ≥50 years are treated with a statin or statin plus ezetimibe combination 1 . This recommendation is based on robust evidence and is consistent with other guidelines that do not recommend the use of risk assessment tools in this population. In adults with CKD stages 3-5 aged 18-49 years, KDIGO recommends treatment if they have known coronary artery disease, diabetes mellitus, a previous ischaemic stroke or an estimated 10-year incidence of coronary death or non-fatal myocardial infarction >10%. Although the evidence for this recommendation is fairly weak, it is consistent with most other current guidelines (TAbLe 3) .
In contrast to the KDIGO guidelines, some guidelines advocate the use of lifetime-estimated risk of cardiovascular disease, rather than 10-year risk, to inform treatment decisions 8 . The rationale is that estimates of 10-year risk might offer false reassurance over the longer term, especially in young patients who have a high lifetime risk 361 . This point might be particularly relevant for young patients with CKD in whom cardiovascular morbidity and mortality increase with age and deteriorating renal function 9 . As statins and other cardioprotective drugs have become considerably less expensive and evidence of their long-term safety and efficacy has increased over time, considerable scope exists to extend their use beyond the traditional 10-year cardiovascular risk threshold. Furthermore, lipid levels change over time in response to certain treatments (such as immunosuppressive therapies), disease progression or remission and the development of malnutrition, which is common in patients with CKD and ESRD but can be substantially reversed 362 . Until concrete evidence exists regarding the use of lipid-lowering therapy in these patients, treatment decisions are likely to continue to be based on acceptability, cost-effectiveness and practicality.
The KDIGO guideline also recommends treatment for patients with CKD stages 1-2 (eGFR >60 ml/min/ 1.73 m 2 ) aged ≥50 years who have pathological albuminuria (urinary albumin:creatinine ratio >30 mg/g). This recommendation is based on observational studies given the absence of RCTs specifically targeting this popu lation. Although such treatment might be reasonable given the increased cardiovascular risk of these patients, the application of risk calculators as for the general population could equally be justified and would perhaps be more prudent. A CKD-cardiovascular disease model, incorporating albuminuria, has been developed as a resource for evaluating the health outcomes and cost-effectiveness of interventions in CKD 363 . However, this model is based on data from the SHARP trial and is only applicable to patients with CKD stage 3b or higher.
The KDIGO guideline does not specify an upper age limit for lipid-lowering therapy, whereas most guidelines recommend treating individuals aged >75 years only for secondary prevention. This difference is related to the lack of validated risk calculators for older individuals and their exclusion from many trials. Given the concerns regarding high-intensity statin usage in patients with CKD because of their increased polypharmacy and comorbidity, a reasonable approach might be to tailor treatment in elderly individuals based on their individual preferences.
The KDIGO guideline focuses on cardiovascular risk to guide treatment and does not recommend treatment of any patient on the basis of a 'high' cholesterol level per se. However, the 2016 European Guidelines on cardiovascular risk prevention suggest lifestyle advice and possible drug treatment if LDL cholesterol level is ≥4.9 mmol/l (≥190 mg/dl) even if the estimated 10-year cardiovascular risk is <1% 3 . Furthermore, this guideline suggests that most patients with a 10-year cardiovascular risk of 5-10% would benefit from lipid-lowering therapy if baseline LDL cholesterol is 2.6-4 mmol/l (100-155 mg/dl). This conclusion is based on the strong, robust and graded association between LDL cholesterol levels and cardiovascular risk; the results of observational studies and trials of lipid-lowering therapies using angiographic and clinical end points; and the results of meta-analyses demonstrating a dose-dependent reduction of cardiovascular risk with LDL cholesterol reduction [152] [153] [154] [155] 360 . These differing recommendations are relevant to the treatment of young patients with CKD and of patients on dialysis with substantial hypercholesterolaemia who would not receive lipid-lowering therapy based on the KDIGO guidelines. In these populations, tailoring of treatment based on patient preferences should perhaps be considered.
In patients receiving statins, KDIGO advises reducing the dose if eGFR is <60 ml/min/1.73 m 2 , based on the reduced renal excretion of some statins, the increased polypharmacy and comorbidity of patients with CKD and the doses of statins used in trials in CKD populations. This recommendation essentially means that high-intensity statin therapy should be avoided. As moderate-dose statin therapy is known to produce a mean reduction in LDL cholesterol of 30% 5 , a substantial proportion of treated patients will not experience a reduction in LDL cholesterol levels of this magnitude. This point is important in certain situations, including after an acute coronary syndrome. For example, the TNT trial found that a large group of patients with eGFRs of 45-59 ml/min/1.73 m 2 (CKD stage 3a) gained substantial benefit from high-dose atorvastatin therapy in terms of a reduction of excess cardiovascular events 160 . Furthermore, the prescribing information for atorvastatin states that no dose adjustment is required for patients with CKD, whereas dose reduction for rosuvastatin is only required if the GFR is <30 ml/min/1.73 m 2 . Indeed, given that statins are now inexpensive (in stark contrast with emerging lipid-lowering therapies), an argument could be made for adopting or studying an approach whereby statin-based regimens are chosen to maximize the absolute reduction in LDL cholesterol to achieve the largest treatment benefits in patients with CKD (rather than any target or goal-based approach). However, this approach is not necessarily without risk and may need to be reserved for patients with high LDL cholesterol levels. In addition to the intended inhibition of cholesterol production, statins inhibit the synthesis of byproducts of alternative (that is, ubiquinone and dolichols) and intermediary (for example, farnesyl-pyrophosphate and geranylgeranyl-pyrophosphates) pathways of mevalonate metabolism 364, 365 , which have important functions including protein synthesis and transport, regulation of cell and tissue growth, mitochondrial function and gene transcription 366, 367 . These unintended effects may result in serious adverse effects, including myopathy or rhabdomyolysis and hepatotoxicity, especially when statins are used at high doses in vulnerable patients with CKD or ESRD and low LDL cholesterol levels 364, 367 . The KDIGO guideline recommends that statins or combination therapy with a statin and ezetimibe should not be initiated in patients on dialysis 1 . However, they suggest that patients who are already receiving such therapy at the time of dialysis initiation should not discontinue. This recommendation is based on the SHARP trial in which 2,141 patients with CKD progressed to needing dialysis during the study period but were analysed in the non-dialysis group in which overall benefit was observed 169 . These two recommendations seem rather incongruous and somewhat difficult to reconcile with the remaining KDIGO guidance. They partly reflect the very limited RCT evidence available rather than the totality of evidence.
One possible explanation as to why a patient on dialysis might benefit from statin-based treatment only if they were receiving this therapy before dialysis initiation relates to the duration of treatment and/or exposure to risk. Although all RCTs of cholesterol-lowering therapies in patients on dialysis have been conducted over a period of around 5 years, the period of exposure to risk in the study participants is much longer, with the atherosclerotic process having started years or decades earlier. As such, the 2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidaemia 9 suggest initiating treatment in patients on dialysis if they are likely to either remain on dialysis for many years or receive a transplant. Indeed, this suggestion seems to align with the KDIGO recommendation of treating all adult kidney transplant recipients with a statin. It also seems to be particularly relevant for diabetic patients on dialysis with high LDL cholesterol levels (>3.76 mmol/l (>145 mg/dl)) 165 .
Conclusions
Patients with all stages of CKD, including those with ESRD on dialysis, and kidney transplant recipients remain at high cardiovascular risk. Despite this risk, these patients have repeatedly been shown to be less likely than patients without CKD to receive statin therapy for primary or secondary prevention of cardiovascular events 368 . In this context of under-treatment, the 2013 KDIGO guideline provides pragmatic guidance for lipid-lowering treatment. However, some of the KDIGO recommend ations, especially for situations with a poor evidence base, can be considered too restrictive when compared to other guidelines aimed at the general population.
Starting lipid-lowering therapy can be a complex process, particularly in patients with no previous cardiovascular events. Shared decision making is especially important when the risks and costs of an intervention are immediate and the benefits are in the future. Two patients may choose different strategies and both are right based on their preferences. As a rule, clinicians should help to inform choices but avoid dictating treatments. Similarly, the role of guidelines is to inform choices but not to dictate them, especially in areas where the evidence is weak.
Several novel therapies to manage dyslipidaemia are in clinical development. To be useful for patients with CKD, these agents must be safe, effective, available and of proven benefit in clinical trials in this population. Many of the novel treatments are biologics that are very expensive to produce. Thus, even if these agents are proven to be safe and effective, as well as being readily available, the high manufacturing costs may make them unaffordable, restricting their widespread use. The very real challenge for physicians managing patients with CKD and ESRD is to ensure that we get the evidence required to support or refute the use of next-generation lipid-lowering agents in this population without having to rely on extrapolation from studies in the general popu lation. We must avoid, as has too often happened in the past, the widespread use of expensive and unproven treatments that later turn out to be unsafe or ineffective. The responsibility for ensuring safety and efficacy rests largely with manufacturers and regulatory authorities. However, as health-care professionals we too must push for, conduct and commit to large RCTs to answer these important questions. Importantly, all physicians looking after patients with CKD or ESRD must enrol all patients who are willing to participate into RCTs if we are to deliver the best possible care with the resources available.
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